BioCentury
ARTICLE | Clinical News

Ardelyx discontinues development of hyperkalemia candidate RDX7675

December 1, 2017 9:51 PM UTC

In a pipeline update Nov. 21, Ardelyx Inc. (NASDAQ:ARDX) said it will discontinue development of hyperkalemia candidate RDX7675 after observing an unexpected, treatment-related side effect of reduced serum bicarbonate levels in a Phase II trial. The company said the side effect could limit the product's chronic use.

Ardelyx said RDX7675 did significantly reduce serum potassium levels across all dose levels in the placebo-controlled Phase II trial in about 60 patients with hyperkalemia. The oral non-absorbed, potassium-binding polymer based on polystyrene sulfonate was also in a Phase III trial for the indication...

BCIQ Company Profiles

Ardelyx Inc.

BCIQ Target Profiles

Potassium channel